An assessment of physician reasons for prescribing Insulin Lispro 200 units/ml in Germany

Jieling Chena Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, USACorrespondence[email protected]

Magaly Perez-Nievesa Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

Carolina Piras De Oliveiraa Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

Erik Spaepenb Global Medical Affairs, HaaPACS GmbH, Schriesheim, GermanyView further author information

Beatrice Osumilic Global Patient Outcomes and Real World Evidence, International, Eli Lilly and Company Ltd, Windesham, Surrey, UKView further author information

Jiat-Ling Poona Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, Indiana, USAView further author information

Nanette Schlootd Medical Affairs, Lilly Deutschland GmbH, Bad Homburg Vor Der Höhe, GermanyView further author information

Nuria Larae Real World Evidence Solutions, IQVIA, Real-World Evidence Solutions, Barcelona, SpainView further author information

Laura Garcia Alvareze Real World Evidence Solutions, IQVIA, Real-World Evidence Solutions, Barcelona, SpainView further author information

Montserrat Rosete Real World Evidence Solutions, IQVIA, Real-World Evidence Solutions, Barcelona, Spain

Your download is now in progress and you may close this window